Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decline of 27.5% from the October 15th total of 48,700 shares. Based on an average daily volume of 31,100 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short.
Avalo Therapeutics Trading Down 0.5 %
NASDAQ AVTX traded down $0.03 during trading on Monday, hitting $5.77. The company's stock had a trading volume of 6,065 shares, compared to its average volume of 41,556. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 0.97. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $5.19. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $27.84.
Get
Avalo Therapeutics alerts:
Analysts Set New Price Targets
Separately, Oppenheimer lowered their price target on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday, November 9th.
Institutional Investors Weigh In On Avalo Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new stake in Avalo Therapeutics in the second quarter worth about $506,000. Goldman Sachs Group Inc. lifted its holdings in shares of Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after purchasing an additional 124,769 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after purchasing an additional 327,241 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Avalo Therapeutics during the third quarter worth about $52,000. Finally, Leo Brokerage LLC acquired a new stake in shares of Avalo Therapeutics during the first quarter worth about $45,000.
About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Recommended Stories
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
